Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

NCT07142811 is registered in ClinicalTrials.gov with Vir Biotechnology, Inc. as lead sponsor.

NCT NCT07142811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07142811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)
Lead sponsor
Vir Biotechnology, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 5, 2025
Completion date
July 31, 2030
Enrollment
100 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

viral hepatitis